NO964445L - DNA sequence, vector, host cell and method for transfecting hematopoietic cells with exogenous DNA - Google Patents

DNA sequence, vector, host cell and method for transfecting hematopoietic cells with exogenous DNA

Info

Publication number
NO964445L
NO964445L NO964445A NO964445A NO964445L NO 964445 L NO964445 L NO 964445L NO 964445 A NO964445 A NO 964445A NO 964445 A NO964445 A NO 964445A NO 964445 L NO964445 L NO 964445L
Authority
NO
Norway
Prior art keywords
vector
host cell
hematopoietic cells
dna
dna sequence
Prior art date
Application number
NO964445A
Other languages
Norwegian (no)
Other versions
NO964445D0 (en
NO303831B1 (en
Inventor
Krisztina M Zsebo
Robert A Bosselman
Sidney Suggs
Francis Hall Martin
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO964445L publication Critical patent/NO964445L/en
Publication of NO964445D0 publication Critical patent/NO964445D0/en
Publication of NO303831B1 publication Critical patent/NO303831B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • C12N15/03—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
NO964445A 1989-10-16 1996-10-18 Isolated DNA sequence, vector, host cell, polypeptide and in vitro use of the polypeptide by a method for transfection of hematopoietic cells with exogenous DNA NO303831B1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42238389A 1989-10-16 1989-10-16
US53719890A 1990-06-11 1990-06-11
US57361690A 1990-08-24 1990-08-24
PCT/US1990/005548 WO1991005795A1 (en) 1989-10-16 1990-09-28 Stem cell factor
NO912321A NO303830B1 (en) 1989-10-16 1991-06-14 Method of Preparation of a Polypeptide with the Biological Hematopoeia Activity Õ Stimulate Growth of Early Hematopoeia Loss Percells

Publications (3)

Publication Number Publication Date
NO964445L true NO964445L (en) 1996-10-18
NO964445D0 NO964445D0 (en) 1996-10-18
NO303831B1 NO303831B1 (en) 1998-09-07

Family

ID=27411345

Family Applications (3)

Application Number Title Priority Date Filing Date
NO912321A NO303830B1 (en) 1989-10-16 1991-06-14 Method of Preparation of a Polypeptide with the Biological Hematopoeia Activity Õ Stimulate Growth of Early Hematopoeia Loss Percells
NO964445A NO303831B1 (en) 1989-10-16 1996-10-18 Isolated DNA sequence, vector, host cell, polypeptide and in vitro use of the polypeptide by a method for transfection of hematopoietic cells with exogenous DNA
NO19982350A NO316022B1 (en) 1989-10-16 1998-05-22 Polypeptide having ± one or more of the biological activities of naturally occurring stem cell factor, including hematopoietic activity, antibody that binds it, and method for producing the polypeptide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO912321A NO303830B1 (en) 1989-10-16 1991-06-14 Method of Preparation of a Polypeptide with the Biological Hematopoeia Activity Õ Stimulate Growth of Early Hematopoeia Loss Percells

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO19982350A NO316022B1 (en) 1989-10-16 1998-05-22 Polypeptide having ± one or more of the biological activities of naturally occurring stem cell factor, including hematopoietic activity, antibody that binds it, and method for producing the polypeptide

Country Status (17)

Country Link
US (1) US20080305074A1 (en)
JP (1) JP2657113B2 (en)
KR (2) KR100193050B1 (en)
AU (3) AU6541090A (en)
CA (8) CA2026915C (en)
ES (2) ES2147720T3 (en)
FI (2) FI108140B (en)
GE (2) GEP20002145B (en)
HU (2) HUT62011A (en)
IE (2) IE20010893A1 (en)
IL (4) IL95905A (en)
LV (1) LV10462B (en)
NO (3) NO303830B1 (en)
NZ (1) NZ235571A (en)
PT (1) PT95524B (en)
RU (1) RU2212411C2 (en)
WO (1) WO1991005795A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107642A0 (en) * 1992-11-20 1994-02-27 Amgen Inc Progenitor b cell stimulating factor
US6012450A (en) * 1993-01-29 2000-01-11 Aradigm Corporation Intrapulmonary delivery of hematopoietic drug
EP0992584A3 (en) * 1993-05-19 2000-06-07 Schering Corporation Purified mammalian FLT3 ligands and agonists and antagonists thereof
US6562596B1 (en) 1993-10-06 2003-05-13 Amgen Inc. Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
US5459031A (en) * 1993-11-05 1995-10-17 Amgen Inc. Methods for controlling sialic acid derivatives in recombinant glycoproteins
JPH07165602A (en) * 1993-12-16 1995-06-27 Kirin Brewery Co Ltd Radiation damage protecting agent
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
US5525708A (en) * 1994-03-28 1996-06-11 Cytomed, Inc. Covalent dimer of kit ligand
EP0817655B1 (en) * 1995-03-31 2004-05-19 Aradigm Corporation Intrapulmonary delivery of hematopoietic drug
US5824789A (en) * 1995-06-07 1998-10-20 Systemix, Inc. Human growth factors, nucleotide sequence encoding growth factors, and method of use thereof
GB9515839D0 (en) * 1995-08-02 1995-10-04 Q One Biotech Ltd Feline stem cell factor
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5885962A (en) * 1996-04-05 1999-03-23 Amgen Inc. Stem cell factor analog compositions and method
US5969105A (en) * 1996-10-25 1999-10-19 Feng; Yiqing Stem cell factor receptor agonists
US6967092B1 (en) 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
JPH10158188A (en) * 1996-11-29 1998-06-16 Senju Pharmaceut Co Ltd Composition for treating cornea
US6017876A (en) 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
WO1999012567A1 (en) * 1997-09-10 1999-03-18 Uab Research Foundation Regulation of osteoclast formation by inhibition of osteoblastic stem cell factor
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
AU784195B2 (en) 1999-11-12 2006-02-16 Baxter Biotech Technology S.A.R.L. Reduced side-effect hemoglobin compositions
EP1301525B1 (en) 2000-07-06 2015-09-02 Sarepta Therapeutics, Inc. Transforming growth factor beta (tgf-beta) blocking agent-treated stem cell composition and method
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US7081443B2 (en) 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule
US20060003008A1 (en) 2003-12-30 2006-01-05 Gibson John W Polymeric devices for controlled release of active agents
EP1819355A4 (en) 2004-09-28 2009-08-12 Genexel Sein Inc Methods of using chimeric coiled-coil molecule
US20060153799A1 (en) 2004-11-05 2006-07-13 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
WO2007098548A1 (en) * 2006-03-01 2007-09-07 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
EP2621515B1 (en) 2010-09-28 2017-03-29 Aegerion Pharmaceuticals, Inc. A chimeric seal-human leptin polypeptide with increased solubility
GB2559498B (en) * 2011-01-10 2018-10-24 Univ Michigan Regents Stem cell factor inhibitor
JP2016511636A (en) * 2013-02-04 2016-04-21 ロジャー ウィリアムズ メディカル センターＲｏｇｅｒ Ｗｉｌｌｉａｍｓ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ Methods and compositions for treating gastrointestinal stromal tumors (GIST)
WO2015006554A1 (en) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
AU2017301040B2 (en) * 2016-07-19 2023-01-05 Accellta Ltd. Culture media for culturing pluripotent stem cells in suspension
BR112022004776A2 (en) * 2019-09-16 2022-06-21 Opsidio Llc Anti-Stem Cell Factor Antibodies and Methods for Using Them

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2245815A1 (en) * 1972-09-19 1974-03-28 Bodenseewerk Perkin Elmer Co METHOD AND DEVICE FOR IDENTIFYING AND EVALUATING PEAKS IN CHROMATOGRAMS
JPS6030291B2 (en) * 1978-03-20 1985-07-16 森永乳業株式会社 HGI glycoprotein that promotes differentiation and proliferation of human granulocytes, method for producing HGI glycoprotein, and therapeutic agent for leukopenia containing HGI glycoprotein
US4634665A (en) * 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4338397A (en) * 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US4353242A (en) * 1980-12-16 1982-10-12 University Of Utah Research Foundation Multichannel detection and resolution of chromatographic peaks
US4438032A (en) * 1981-01-30 1984-03-20 The Regents Of The University Of California Unique T-lymphocyte line and products derived therefrom
US4722998A (en) * 1982-10-20 1988-02-02 Dana Farber Cancer Institute Method of producing lymphocyte growth factors
US4695542A (en) * 1983-10-04 1987-09-22 Dnax Research Institute Of Molecular And Cellular Biology, Inc. cDNA clones coding for polypeptides exhibiting multi-lineage cellular growth factor activity
US4714680B1 (en) * 1984-02-06 1995-06-27 Univ Johns Hopkins Human stem cells
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
JPH0753667B2 (en) * 1985-08-09 1995-06-07 新技術開発事業団 Bone marrow transplant therapy adjuvant
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS62223126A (en) * 1986-03-25 1987-10-01 Sankyo Co Ltd Growth factor for blood stem cell
US4721096A (en) * 1986-04-18 1988-01-26 Marrow-Tech Incorporated Process for replicating bone marrow in vitro and using the same
US4879227A (en) * 1986-05-06 1989-11-07 Genetics Institute, Inc. Production of a recombinant human colony stimulating factor
US4959455A (en) * 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4877729A (en) * 1986-07-14 1989-10-31 Genetics Institute, Inc. Recombinant DNA encoding novel family of primate hematopoietic growth factors
US4808611A (en) * 1986-07-30 1989-02-28 Immunex Corporation Use of interleukin-1 to induce development of multipotent hemopoietic cell populations
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
DE3810094A1 (en) * 1988-03-25 1989-10-05 Agfa Gevaert Ag X-RAY IMAGING FILM WITH A STIMULATABLE PHOSPHORIC LAYER AND DEVICE FOR THEIR TREATMENT AND EVALUATION
US5087570A (en) * 1988-05-10 1992-02-11 Weissman Irving L Homogeneous mammalian hematopoietic stem cell composition
US4874325A (en) * 1988-09-23 1989-10-17 General Motors Corporation Electrical connector with interface seal
US5119315A (en) * 1989-04-28 1992-06-02 Amoco Corporation Method of correlating a record of sample data with a record of reference data
US6852313B1 (en) * 1989-10-16 2005-02-08 Amgen Inc. Method of stimulating growth of melanocyte cells by administering stem cell factor
US6248319B1 (en) * 1989-10-16 2001-06-19 Krisztina M. Zsebo Method for increasing hematopoietic progenitor cells by stem cell factor polypeptides
US20030125519A1 (en) * 1990-08-27 2003-07-03 Peter Besmer Ligand for the c-kit receptor and methods of use thereof
US5767074A (en) * 1990-08-27 1998-06-16 Sloan-Kettering Institute For Cancer Research Compositions of soluble C-kit ligand and hematopoietic factors
US5121337A (en) * 1990-10-15 1992-06-09 Exxon Research And Engineering Company Method for correcting spectral data for data due to the spectral measurement process itself and estimating unknown property and/or composition data of a sample using such method
DE69226431T2 (en) * 1991-04-05 1999-04-22 The Board Of Regents Of The University Of Washington, Seattle, Wash. CELL RECEPTOR SPECIFIC MONOCLONAL ANTIBODIES AGAINST STEM CELL FACTOR RECEPTOR
US5545533A (en) * 1991-05-25 1996-08-13 Boehringer Mannheim Gmbh Monoclonal antibodies against c-kit and method of detecting a malignancy using c-kit specific antibodies
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5772992A (en) * 1992-11-24 1998-06-30 G.D. Searle & Co. Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors
US5599703A (en) * 1993-10-28 1997-02-04 The United States Of America As Represented By The Secretary Of The Navy In vitro amplification/expansion of CD34+ stem and progenitor cells
JPH07165602A (en) * 1993-12-16 1995-06-27 Kirin Brewery Co Ltd Radiation damage protecting agent
US5610056A (en) * 1994-11-16 1997-03-11 Amgen Inc. Use of stem cell factor interleukin-6 and soluble interleukin-6 receptor to induce the development of hematopoietic stem cells
US5911988A (en) * 1995-04-28 1999-06-15 Bayer Corporation Method for treating asthma using SCF antibody
DE19600589C1 (en) * 1996-01-10 1997-01-16 Univ Eberhard Karls Antibody A3C6E2

Also Published As

Publication number Publication date
AU674570B2 (en) 1997-01-02
KR100210241B1 (en) 1999-07-15
NO964445D0 (en) 1996-10-18
KR100193050B1 (en) 1999-06-15
CA2267651A1 (en) 1991-04-17
IL127924A (en) 2006-12-31
CA2267643A1 (en) 1991-04-17
LV10462A (en) 1995-02-20
IE903562A1 (en) 1991-04-24
AU6060394A (en) 1994-07-07
GEP20033145B (en) 2003-12-25
US20080305074A1 (en) 2008-12-11
IE20010893A1 (en) 2003-03-05
FI120312B (en) 2009-09-15
LV10462B (en) 1996-04-20
CA2267658A1 (en) 1991-04-17
GEP20002145B (en) 2000-06-25
KR920701238A (en) 1992-08-11
FI20011804A (en) 2001-09-13
ES2314999T3 (en) 2009-03-16
NZ235571A (en) 1997-06-24
NO316022B1 (en) 2003-12-01
HUT62011A (en) 1993-03-29
AU712721B2 (en) 1999-11-11
JPH04502628A (en) 1992-05-14
NO303830B1 (en) 1998-09-07
WO1991005795A1 (en) 1991-05-02
CA2267626A1 (en) 1991-04-17
CA2267668C (en) 2008-02-19
IL95905A (en) 2002-02-10
PT95524B (en) 1997-08-29
FI108140B (en) 2001-11-30
NO912321L (en) 1991-08-16
NO303831B1 (en) 1998-09-07
NO982350D0 (en) 1998-05-22
AU1771297A (en) 1997-06-19
CA2267651C (en) 2008-01-29
IL127924A0 (en) 2000-02-17
IL95905A0 (en) 1991-07-18
FI912857A0 (en) 1991-06-13
CA2267671C (en) 2008-12-02
CA2026915A1 (en) 1991-04-17
RU2212411C2 (en) 2003-09-20
PT95524A (en) 1991-09-13
NO912321D0 (en) 1991-06-14
CA2267671A1 (en) 1991-04-17
HU220234B (en) 2001-11-28
CA2267670A1 (en) 1991-04-17
CA2026915C (en) 2006-11-28
CA2267668A1 (en) 1991-04-17
ES2147720T3 (en) 2000-10-01
IL170681A (en) 2010-04-15
JP2657113B2 (en) 1997-09-24
CA2267670C (en) 2005-01-11
NO982350L (en) 1998-05-22
HU912386D0 (en) 1991-12-30
AU6541090A (en) 1991-05-16

Similar Documents

Publication Publication Date Title
NO964445L (en) DNA sequence, vector, host cell and method for transfecting hematopoietic cells with exogenous DNA
GB2217718B (en) Recombinant viruses,vaccines containing them and in vitro cell cultures thereof
PT73768B (en) Process for stabilizing and selecting host cells with recombinant dna
DK325189D0 (en) PROCEDURE FOR THE INTRODUCTION OF MOLECULES, IN PARTICULAR GENETIC MATERIAL, IN CELL MATERIAL AND APPARATUS FOR USE IN EXERCISING THE PROCEDURE
EP0484374A4 (en) Rapid, versatile and simple system for expressing genes in eukaryotic cells
DE69019009D1 (en) Cell culture method.
EP0953041A4 (en) Serum-free mammalian cell culture medium, and uses thereof
DK374087A (en) PROCEDURE FOR MANUFACTURING PROTEINS WITH FACTOR VIII ACTIVITY USING MICROBIAL HOUSING CELLS AND EXPRESSION VECTORS, HOST CELLS AND ANTIBODIES FOR USING THIS
EP0046681A3 (en) Microcarrier cell culture method
GB8928179D0 (en) Dna,constructs,cells and plants derived therefrom
ZA864525B (en) Vector for expression of interferon-ypsilon in mammalian cells,method for using it and product obtained
DK159976C (en) PLASMID VECTORS, METHOD OF PRODUCING THEREOF, BACTERY CELLS TRANSFORMED WITH PLASMID VECTORS, AND EXPRESSION OF PROTEIN IN TRANSFORMED BACTERY CELLS
IL92703A0 (en) Cell culture medium and its use in culturing mammalian cells
DE3853474D1 (en) VECTOR FOR INTEGRATION-INDEPENDENT GENE EXPRESSION IN MAMMAL HOST CELLS.
ZA908316B (en) Dna,constructs,cells and plants derived therefrom
NO174970C (en) Recombinant DNA, recombinant DNA vector and host cell
EP0269086A3 (en) Cell culture apparatus
EP0340783A3 (en) Apparatus for culturing animal cells, method of culturing thereof and diagnostics of the culture
EP0300588A3 (en) Cell culturing apparatus and method
AU5945386A (en) Lymphotoxin dna, lymphotoxin expression vector, lymphotoxin resistant cell, transformant with lymphotoxin expression vector and process for preparing lymphotoxin
GB2183674B (en) Microcarrier for cell culture.
NO961749L (en) Improved cell culture method and medium
EP0116411A3 (en) Dna expression vectors useful in bacillus cells
IL83435A (en) Dna construct for expression of genes in yeast, an expression vector containing it and yeast transformed with said expression vector
AU589355B2 (en) Recombinant DNA expression vectors and method for gene expression

Legal Events

Date Code Title Description
MK1K Patent expired